FI3829563T3 - 3-sulfopropaanihappo neurodegeneratiivisten sairauksien hoitamiseksi - Google Patents
3-sulfopropaanihappo neurodegeneratiivisten sairauksien hoitamiseksi Download PDFInfo
- Publication number
- FI3829563T3 FI3829563T3 FIEP19752795.5T FI19752795T FI3829563T3 FI 3829563 T3 FI3829563 T3 FI 3829563T3 FI 19752795 T FI19752795 T FI 19752795T FI 3829563 T3 FI3829563 T3 FI 3829563T3
- Authority
- FI
- Finland
- Prior art keywords
- subject
- spa
- need
- pharmaceutically acceptable
- prevention
- Prior art date
Links
- OURSFPZPOXNNKX-UHFFFAOYSA-N 3-sulfopropanoic acid Chemical compound OC(=O)CCS(O)(=O)=O OURSFPZPOXNNKX-UHFFFAOYSA-N 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713061P | 2018-08-01 | 2018-08-01 | |
| PCT/US2019/044023 WO2020028290A1 (en) | 2018-08-01 | 2019-07-30 | Methods for treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3829563T3 true FI3829563T3 (fi) | 2025-02-17 |
Family
ID=67614642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19752795.5T FI3829563T3 (fi) | 2018-08-01 | 2019-07-30 | 3-sulfopropaanihappo neurodegeneratiivisten sairauksien hoitamiseksi |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12083082B2 (https=) |
| EP (1) | EP3829563B1 (https=) |
| JP (1) | JP7573512B2 (https=) |
| KR (1) | KR102716959B1 (https=) |
| CN (1) | CN112867485A (https=) |
| AU (1) | AU2019315853B2 (https=) |
| BR (1) | BR112021001739A2 (https=) |
| CL (1) | CL2021000269A1 (https=) |
| DK (1) | DK3829563T3 (https=) |
| EA (1) | EA202190406A1 (https=) |
| ES (1) | ES3011716T3 (https=) |
| FI (1) | FI3829563T3 (https=) |
| HR (1) | HRP20250206T1 (https=) |
| HU (1) | HUE070101T2 (https=) |
| IL (1) | IL280424B2 (https=) |
| LT (1) | LT3829563T (https=) |
| MX (1) | MX2021001287A (https=) |
| MY (1) | MY206530A (https=) |
| PH (1) | PH12021550213A1 (https=) |
| PL (1) | PL3829563T3 (https=) |
| PT (1) | PT3829563T (https=) |
| RS (1) | RS66516B1 (https=) |
| SG (1) | SG11202100767XA (https=) |
| SI (1) | SI3829563T1 (https=) |
| SM (1) | SMT202500080T1 (https=) |
| UA (1) | UA130011C2 (https=) |
| WO (1) | WO2020028290A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021025504A2 (pt) * | 2019-06-17 | 2022-04-26 | Alzheon Inc | Métodos para tratar distúrbios neurodegenerativos |
| MX2024007070A (es) * | 2021-12-09 | 2024-08-22 | Alzheon Inc | Alz-801 para uso en el tratamiento de la enfermedad de alzheimer. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| PT2089417E (pt) | 2006-10-12 | 2015-04-14 | Bhi Ltd Partnership | Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico |
| WO2013177367A2 (en) | 2012-05-23 | 2013-11-28 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
| WO2014121083A1 (en) | 2013-01-31 | 2014-08-07 | President And Fellows Of Harvard College | Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition |
| CA2941415A1 (en) * | 2014-03-21 | 2015-09-24 | Alzheon, Inc. | Methods for treating neurological disorders |
| FI3347002T3 (fi) | 2015-09-10 | 2023-08-10 | Alzheon Inc | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa |
-
2019
- 2019-07-30 JP JP2021505721A patent/JP7573512B2/ja active Active
- 2019-07-30 HU HUE19752795A patent/HUE070101T2/hu unknown
- 2019-07-30 SG SG11202100767XA patent/SG11202100767XA/en unknown
- 2019-07-30 FI FIEP19752795.5T patent/FI3829563T3/fi active
- 2019-07-30 CN CN201980064415.6A patent/CN112867485A/zh active Pending
- 2019-07-30 SM SM20250080T patent/SMT202500080T1/it unknown
- 2019-07-30 US US17/264,477 patent/US12083082B2/en active Active
- 2019-07-30 EA EA202190406A patent/EA202190406A1/ru unknown
- 2019-07-30 EP EP19752795.5A patent/EP3829563B1/en active Active
- 2019-07-30 BR BR112021001739-9A patent/BR112021001739A2/pt unknown
- 2019-07-30 RS RS20250164A patent/RS66516B1/sr unknown
- 2019-07-30 PT PT197527955T patent/PT3829563T/pt unknown
- 2019-07-30 AU AU2019315853A patent/AU2019315853B2/en active Active
- 2019-07-30 WO PCT/US2019/044023 patent/WO2020028290A1/en not_active Ceased
- 2019-07-30 IL IL280424A patent/IL280424B2/en unknown
- 2019-07-30 KR KR1020217005803A patent/KR102716959B1/ko active Active
- 2019-07-30 MY MYPI2021000515A patent/MY206530A/en unknown
- 2019-07-30 DK DK19752795.5T patent/DK3829563T3/da active
- 2019-07-30 LT LTEPPCT/US2019/044023T patent/LT3829563T/lt unknown
- 2019-07-30 ES ES19752795T patent/ES3011716T3/es active Active
- 2019-07-30 PL PL19752795.5T patent/PL3829563T3/pl unknown
- 2019-07-30 SI SI201930898T patent/SI3829563T1/sl unknown
- 2019-07-30 HR HRP20250206TT patent/HRP20250206T1/hr unknown
- 2019-07-30 MX MX2021001287A patent/MX2021001287A/es unknown
- 2019-07-30 UA UAA202101015A patent/UA130011C2/uk unknown
-
2021
- 2021-01-28 PH PH12021550213A patent/PH12021550213A1/en unknown
- 2021-02-01 CL CL2021000269A patent/CL2021000269A1/es unknown
-
2024
- 2024-08-02 US US18/793,452 patent/US20250213507A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lahiri et al. | How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the" LEARn" model (latent early-life associated regulation) may explain the triggering of AD | |
| Mi et al. | The emerging roles of ferroptosis in Huntington’s disease | |
| Dolan et al. | Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486 | |
| Foster et al. | The role of sequestosome 1/p62 protein in amyotrophic lateral sclerosis and frontotemporal dementia pathogenesis | |
| WO2007149798A3 (en) | Biomarkers for the progression of alzheimer's disease | |
| WO2008046038A3 (en) | Intranasal therapeutics for neuroprotection | |
| MA34828B1 (fr) | Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer | |
| Crowley | Long-term drug treatment of patients with alcohol dependence | |
| FI3829563T3 (fi) | 3-sulfopropaanihappo neurodegeneratiivisten sairauksien hoitamiseksi | |
| Wang et al. | Role of MLL in the modification of H3K4me3 in aluminium-induced cognitive dysfunction | |
| WO2006054277A3 (en) | Treatment of neurodegenerative disease with angiogenin and its mutants | |
| Kun-Rodrigues et al. | Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies | |
| Mohamed et al. | Effects of enhanced environment and induced depression on cuprizone mouse model of demyelination | |
| WO2005019474A3 (en) | Human autism susceptibility gene and uses thereof | |
| WO2011066082A3 (en) | Markers associated with ribavirin-induced anemia | |
| WO2023001987A3 (en) | Therapeutic muteins | |
| WO2006003520A3 (en) | Human autism predisposition gene encoding a transcription factor and uses thereof | |
| TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| Adshead | The adverse effects of mefloquine in deployed military personnel | |
| WO2005095348A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
| Hernández-Rivera et al. | NRAMP1 polymorphisms like susceptibility marker in Mexican focus of cutaneous leishmaniasis | |
| WO2006003523A8 (en) | Human autism susceptibility gene encoding prkcb1 and uses thereof | |
| WO2006090288A3 (en) | Human autism susceptibility genes encoding a neurotransmitter transporter and uses thereof | |
| WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
| WO2006097463A3 (en) | Compositions and methods for treating and diagnosing inflammatory disorders |